サマリー

アフリカのHIV治療薬市場 2023-2027
TechnavioはアフリカのHIV治療薬市場を監視しており、2023年から2027年の間に3億2160万ドルの成長が見込まれ、予測期間中にCAGR 3.76%で加速しています。当レポートでは、アフリカのHIV治療薬市場について、全体的な分析、市場規模と予測、動向、成長ドライバー、課題、さらに約25社のベンダーを網羅したベンダー分析を行っています。
現在の市場シナリオ、最新のトレンドとドライバー、市場全体の環境に関する最新の分析を提供しています。市場は、STDの蔓延の増加、有利な国際的プログラム、政府との協力関係によって牽引されています。
TechnavioのアフリカのHIV治療薬市場は、以下のように区分されています。
薬物クラス別
- 逆転写酵素阻害剤
- プロテアーゼ阻害剤
- インテグラーゼ阻害剤
- 融合阻害剤
- コレセプター拮抗薬
投与経路別
- 経口剤
- 注射剤
地域別
- 南アフリカ
- ナイジェリア
- ケニア
- ウガンダ
- その他のアフリカ地域
本調査では、今後数年間におけるアフリカのHIV治療薬市場の成長を促進する主な理由の1つとして、さまざまな組織による認知度の向上を挙げています。また、HIVの母子感染の撲滅に向けた注目の高まりと高いHIV薬剤耐性が、同市場における大きな需要につながると考えられます。
Technavioは、複数のソースからのデータを調査、合成、要約し、主要パラメータの分析によって、市場の詳細な姿を提示します。アフリカのHIV治療薬市場に関する弊社のレポートは、以下の分野を対象としています。
- HIV治療薬市場のサイジング
- HIV治療薬市場の予測
- HIV治療薬市場の産業分析
Technavioの強力なベンダー分析は、顧客が市場での地位を向上できるように設計されており、これに沿って、本レポートでは、Abbott Laboratories、AbbVie Inc.を含む複数のHIV治療薬市場の主要ベンダーについて詳細な分析を提供しています。アルファファーマ、アスペンファーマケアホールディングス、アストラゼネカ、オーロビンドファーマ、アバケアヘルス、ベーリンガーインゲルハイム、シプラ、ホフマンラロシュ、ギリアドサイエンス、グラクソスミスクライン、ヘテロラボ、ジョンソンアンドジョンソン、メルクアンドカンパニー、SSIダイアグノスティカ、メルクアンドカンパニー、エーザイ、エーザイマシナリー、エーザイマシナリー、エーザイマシナリー、エーザイマシナリー、エーエヌエス、エーエヌエス・エス・エス・エス・エス・エス・エス。Inc.、SSI Diagnostica AS、Sun Pharmaceutical Industries Ltd.、Teva Pharmaceutical Industries Ltd.、Theratechnologies Inc.、Viatris Inc.の7社です。また、アフリカのHIV治療薬市場の分析レポートには、今後の動向と市場成長に影響を与える課題に関する情報も含まれています。これは、企業が今後訪れるすべての成長機会を戦略的に活用するのに役立つものです。
本調査は、業界の主要参加者からのインプットを含め、一次情報と二次情報の客観的な組み合わせを使用して実施しました。本レポートには、主要ベンダーの分析に加え、包括的な市場およびベンダーランドスケープが含まれています。本レポートの詳細については、https://www.technavio.com/report/africa-hiv-treatment-drugs-market-industry-analysis をご覧ください。
Technavioは、利益、価格、競争、プロモーションなどの主要パラメータの分析により、複数のソースからのデータの研究、合成、総括の方法により、市場の詳細な姿を提示します。また、業界の主要なインフルエンサーを特定することにより、市場の様々な側面を提示します。提示されるデータは、包括的で信頼性が高く、一次および二次にわたる広範な調査の結果です。Technavioの市場調査レポートは、正確な市場成長を予測するために、完全な競争環境と、定性的および定量的調査を用いた詳細なベンダー選定方法と分析を提供します。

ページTOPに戻る

目次

• 1 Executive Summary
o 1.1 Market overview
o Exhibit 01: Executive Summary - Chart on Market Overview
o Exhibit 02: Executive Summary - Data Table on Market Overview
o Exhibit 03: Executive Summary - Chart on Country Market Characteristics
o Exhibit 04: Executive Summary - Chart on Market by Geography
o Exhibit 05: Executive Summary - Chart on Market Segmentation by Drug Class
o Exhibit 06: Executive Summary - Chart on Market Segmentation by Route of Administration
o Exhibit 07: Executive Summary - Chart on Incremental Growth
o Exhibit 08: Executive Summary - Data Table on Incremental Growth
o Exhibit 09: Executive Summary - Chart on Vendor Market Positioning
• 2 Market Landscape
o 2.1 Market ecosystem
o Exhibit 10: Parent market
o Exhibit 11: Market Characteristics
• 3 Market Sizing
o 3.1 Market definition
o Exhibit 12: Offerings of vendors included in the market definition
o 3.2 Market segment analysis
o Exhibit 13: Market segments
o 3.3 Market size 2022
o 3.4 Market outlook: Forecast for 2022-2027
o Exhibit 14: Chart on Africa - Market size and forecast 2022-2027 ($ million)
o Exhibit 15: Data Table on Regional - Market size and forecast 2022-2027 ($ million)
o Exhibit 16: Chart on Africa: Year-over-year growth 2022-2027 (%)
o Exhibit 17: Data Table on Regional - Market size and forecast 2022-2027 ($ million)
• 4 Historic Market Size
o 4.1 HIV treatment drugs market in Africa 2017 - 2021
o Exhibit 18: Historic Market Size - Data Table on HIV treatment drugs market in Africa 2017 - 2021 ($ million)
o 4.2 Drug Class Segment Analysis 2017 - 2021
o Exhibit 19: Historic Market Size - Drug Class Segment 2017 - 2021 ($ million)
o 4.3 Route Of Administration Segment Analysis 2017 - 2021
o Exhibit 20: Historic Market Size - Route Of Administration Segment 2017 - 2021 ($ million)
o 4.4 Country Segment Analysis 2017 - 2021
o Exhibit 21: Historic Market Size - Country Segment 2017 - 2021 ($ million)
• 5 Five Forces Analysis
o 5.1 Five forces summary
o Exhibit 22: Five forces analysis - Comparison between 2022 and 2027
o 5.2 Bargaining power of buyers
o Exhibit 23: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
o 5.3 Bargaining power of suppliers
o Exhibit 24: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
o 5.4 Threat of new entrants
o Exhibit 25: Threat of new entrants - Impact of key factors in 2022 and 2027
o 5.5 Threat of substitutes
o Exhibit 26: Threat of substitutes - Impact of key factors in 2022 and 2027
o 5.6 Threat of rivalry
o Exhibit 27: Threat of rivalry - Impact of key factors in 2022 and 2027
o 5.7 Market condition
o Exhibit 28: Chart on Market condition - Five forces 2022 and 2027
• 6 Market Segmentation by Drug Class
o 6.1 Market segments
o Exhibit 29: Chart on Drug Class - Market share 2022-2027 (%)
o Exhibit 30: Data Table on Drug Class - Market share 2022-2027 (%)
o 6.2 Comparison by Drug Class
o Exhibit 31: Chart on Comparison by Drug Class
o Exhibit 32: Data Table on Comparison by Drug Class
o 6.3 Reverse transcriptase inhibitors - Market size and forecast 2022-2027
o Exhibit 33: Chart on Reverse transcriptase inhibitors - Market size and forecast 2022-2027 ($ million)
o Exhibit 34: Data Table on Reverse transcriptase inhibitors - Market size and forecast 2022-2027 ($ million)
o Exhibit 35: Chart on Reverse transcriptase inhibitors - Year-over-year growth 2022-2027 (%)
o Exhibit 36: Data Table on Reverse transcriptase inhibitors - Year-over-year growth 2022-2027 (%)
o 6.4 Protease inhibitors - Market size and forecast 2022-2027
o Exhibit 37: Chart on Protease inhibitors - Market size and forecast 2022-2027 ($ million)
o Exhibit 38: Data Table on Protease inhibitors - Market size and forecast 2022-2027 ($ million)
o Exhibit 39: Chart on Protease inhibitors - Year-over-year growth 2022-2027 (%)
o Exhibit 40: Data Table on Protease inhibitors - Year-over-year growth 2022-2027 (%)
o 6.5 Integrase inhibitors - Market size and forecast 2022-2027
o Exhibit 41: Chart on Integrase inhibitors - Market size and forecast 2022-2027 ($ million)
o Exhibit 42: Data Table on Integrase inhibitors - Market size and forecast 2022-2027 ($ million)
o Exhibit 43: Chart on Integrase inhibitors - Year-over-year growth 2022-2027 (%)
o Exhibit 44: Data Table on Integrase inhibitors - Year-over-year growth 2022-2027 (%)
o 6.6 Fusion inhibitors - Market size and forecast 2022-2027
o Exhibit 45: Chart on Fusion inhibitors - Market size and forecast 2022-2027 ($ million)
o Exhibit 46: Data Table on Fusion inhibitors - Market size and forecast 2022-2027 ($ million)
o Exhibit 47: Chart on Fusion inhibitors - Year-over-year growth 2022-2027 (%)
o Exhibit 48: Data Table on Fusion inhibitors - Year-over-year growth 2022-2027 (%)
o 6.7 Coreceptor antagonists - Market size and forecast 2022-2027
o Exhibit 49: Chart on Coreceptor antagonists - Market size and forecast 2022-2027 ($ million)
o Exhibit 50: Data Table on Coreceptor antagonists - Market size and forecast 2022-2027 ($ million)
o Exhibit 51: Chart on Coreceptor antagonists - Year-over-year growth 2022-2027 (%)
o Exhibit 52: Data Table on Coreceptor antagonists - Year-over-year growth 2022-2027 (%)
o 6.8 Market opportunity by Drug Class
o Exhibit 53: Market opportunity by Drug Class ($ million)
• 7 Market Segmentation by Route of Administration
o 7.1 Market segments
o Exhibit 54: Chart on Route of Administration - Market share 2022-2027 (%)
o Exhibit 55: Data Table on Route of Administration - Market share 2022-2027 (%)
o 7.2 Comparison by Route of Administration
o Exhibit 56: Chart on Comparison by Route of Administration
o Exhibit 57: Data Table on Comparison by Route of Administration
o 7.3 Oral drugs - Market size and forecast 2022-2027
o Exhibit 58: Chart on Oral drugs - Market size and forecast 2022-2027 ($ million)
o Exhibit 59: Data Table on Oral drugs - Market size and forecast 2022-2027 ($ million)
o Exhibit 60: Chart on Oral drugs - Year-over-year growth 2022-2027 (%)
o Exhibit 61: Data Table on Oral drugs - Year-over-year growth 2022-2027 (%)
o 7.4 Injectable drugs - Market size and forecast 2022-2027
o Exhibit 62: Chart on Injectable drugs - Market size and forecast 2022-2027 ($ million)
o Exhibit 63: Data Table on Injectable drugs - Market size and forecast 2022-2027 ($ million)
o Exhibit 64: Chart on Injectable drugs - Year-over-year growth 2022-2027 (%)
o Exhibit 65: Data Table on Injectable drugs - Year-over-year growth 2022-2027 (%)
o 7.5 Market opportunity by Route of Administration
o Exhibit 66: Market opportunity by Route of Administration ($ million)
• 8 Customer Landscape
o 8.1 Customer landscape overview
o Exhibit 67: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 9 Geographic Landscape
o 9.1 Geographic segmentation
o Exhibit 68: Chart on Market share by geography - 2022-2027 (%)
o Exhibit 69: Data Table on Market share by geography - 2022-2027 (%)
o 9.2 Geographic comparison
o Exhibit 70: Chart on Geographic comparison
o Exhibit 71: Data Table on Geographic comparison
o 9.3 South Africa - Market size and forecast 2022-2027
o Exhibit 72: Chart on South Africa - Market size and forecast 2022-2027 ($ million)
o Exhibit 73: Data Table on South Africa - Market size and forecast 2022-2027 ($ million)
o Exhibit 74: Chart on South Africa - Year-over-year growth 2022-2027 (%)
o Exhibit 75: Data Table on South Africa - Year-over-year growth 2022-2027 (%)
o 9.4 Nigeria - Market size and forecast 2022-2027
o Exhibit 76: Chart on Nigeria - Market size and forecast 2022-2027 ($ million)
o Exhibit 77: Data Table on Nigeria - Market size and forecast 2022-2027 ($ million)
o Exhibit 78: Chart on Nigeria - Year-over-year growth 2022-2027 (%)
o Exhibit 79: Data Table on Nigeria - Year-over-year growth 2022-2027 (%)
o 9.5 Kenya - Market size and forecast 2022-2027
o Exhibit 80: Chart on Kenya - Market size and forecast 2022-2027 ($ million)
o Exhibit 81: Data Table on Kenya - Market size and forecast 2022-2027 ($ million)
o Exhibit 82: Chart on Kenya - Year-over-year growth 2022-2027 (%)
o Exhibit 83: Data Table on Kenya - Year-over-year growth 2022-2027 (%)
o 9.6 Uganda - Market size and forecast 2022-2027
o Exhibit 84: Chart on Uganda - Market size and forecast 2022-2027 ($ million)
o Exhibit 85: Data Table on Uganda - Market size and forecast 2022-2027 ($ million)
o Exhibit 86: Chart on Uganda - Year-over-year growth 2022-2027 (%)
o Exhibit 87: Data Table on Uganda - Year-over-year growth 2022-2027 (%)
o 9.7 Rest of Africa - Market size and forecast 2022-2027
o Exhibit 88: Chart on Rest of Africa - Market size and forecast 2022-2027 ($ million)
o Exhibit 89: Data Table on Rest of Africa - Market size and forecast 2022-2027 ($ million)
o Exhibit 90: Chart on Rest of Africa - Year-over-year growth 2022-2027 (%)
o Exhibit 91: Data Table on Rest of Africa - Year-over-year growth 2022-2027 (%)
o 9.8 Market opportunity by geography
o Exhibit 92: Market opportunity by geography ($ million)
• 10 Drivers, Challenges, and Trends
o 10.1 Market drivers
o 10.2 Market challenges
o 10.3 Impact of drivers and challenges
o Exhibit 93: Impact of drivers and challenges in 2022 and 2027
o 10.4 Market trends
• 11 Vendor Landscape
o 11.1 Overview
o 11.2 Vendor landscape
o Exhibit 94: Overview on Criticality of inputs and Factors of differentiation
o 11.3 Landscape disruption
o Exhibit 95: Overview on factors of disruption
o 11.4 Industry risks
o Exhibit 96: Impact of key risks on business
• 12 Vendor Analysis
o 12.1 Vendors covered
o Exhibit 97: Vendors covered
o 12.2 Market positioning of vendors
o Exhibit 98: Matrix on vendor position and classification
o 12.3 Abbott Laboratories
o Exhibit 99: Abbott Laboratories - Overview
o Exhibit 100: Abbott Laboratories - Business segments
o Exhibit 101: Abbott Laboratories - Key news
o Exhibit 102: Abbott Laboratories - Key offerings
o Exhibit 103: Abbott Laboratories - Segment focus
o 12.4 AbbVie Inc.
o Exhibit 104: AbbVie Inc. - Overview
o Exhibit 105: AbbVie Inc. - Product / Service
o Exhibit 106: AbbVie Inc. - Key offerings
o 12.5 Alpha Pharma
o Exhibit 107: Alpha Pharma - Overview
o Exhibit 108: Alpha Pharma - Product / Service
o Exhibit 109: Alpha Pharma - Key offerings
o 12.6 Aspen Pharmacare Holdings Ltd.
o Exhibit 110: Aspen Pharmacare Holdings Ltd. - Overview
o Exhibit 111: Aspen Pharmacare Holdings Ltd. - Business segments
o Exhibit 112: Aspen Pharmacare Holdings Ltd. - Key offerings
o Exhibit 113: Aspen Pharmacare Holdings Ltd. - Segment focus
o 12.7 AstraZeneca Plc
o Exhibit 114: AstraZeneca Plc - Overview
o Exhibit 115: AstraZeneca Plc - Product / Service
o Exhibit 116: AstraZeneca Plc - Key news
o Exhibit 117: AstraZeneca Plc - Key offerings
o 12.8 Aurobindo Pharma Ltd.
o Exhibit 118: Aurobindo Pharma Ltd. - Overview
o Exhibit 119: Aurobindo Pharma Ltd. - Product / Service
o Exhibit 120: Aurobindo Pharma Ltd. - Key offerings
o 12.9 Avacare Health
o Exhibit 121: Avacare Health - Overview
o Exhibit 122: Avacare Health - Product / Service
o Exhibit 123: Avacare Health - Key offerings
o 12.10 Cipla Ltd.
o Exhibit 124: Cipla Ltd. - Overview
o Exhibit 125: Cipla Ltd. - Business segments
o Exhibit 126: Cipla Ltd. - Key news
o Exhibit 127: Cipla Ltd. - Key offerings
o Exhibit 128: Cipla Ltd. - Segment focus
o 12.11 F. Hoffmann La Roche Ltd.
o Exhibit 129: F. Hoffmann La Roche Ltd. - Overview
o Exhibit 130: F. Hoffmann La Roche Ltd. - Business segments
o Exhibit 131: F. Hoffmann La Roche Ltd. - Key news
o Exhibit 132: F. Hoffmann La Roche Ltd. - Key offerings
o Exhibit 133: F. Hoffmann La Roche Ltd. - Segment focus
o 12.12 Gilead Sciences Inc.
o Exhibit 134: Gilead Sciences Inc. - Overview
o Exhibit 135: Gilead Sciences Inc. - Product / Service
o Exhibit 136: Gilead Sciences Inc. - Key news
o Exhibit 137: Gilead Sciences Inc. - Key offerings
o 12.13 GlaxoSmithKline Plc
o Exhibit 138: GlaxoSmithKline Plc - Overview
o Exhibit 139: GlaxoSmithKline Plc - Business segments
o Exhibit 140: GlaxoSmithKline Plc - Key offerings
o Exhibit 141: GlaxoSmithKline Plc - Segment focus
o 12.14 Merck and Co. Inc.
o Exhibit 142: Merck and Co. Inc. - Overview
o Exhibit 143: Merck and Co. Inc. - Business segments
o Exhibit 144: Merck and Co. Inc. - Key news
o Exhibit 145: Merck and Co. Inc. - Key offerings
o Exhibit 146: Merck and Co. Inc. - Segment focus
o 12.15 Sun Pharmaceutical Industries Ltd.
o Exhibit 147: Sun Pharmaceutical Industries Ltd. - Overview
o Exhibit 148: Sun Pharmaceutical Industries Ltd. - Product / Service
o Exhibit 149: Sun Pharmaceutical Industries Ltd. - Key offerings
o 12.16 Theratechnologies Inc.
o Exhibit 150: Theratechnologies Inc. - Overview
o Exhibit 151: Theratechnologies Inc. - Product / Service
o Exhibit 152: Theratechnologies Inc. - Key offerings
o 12.17 Viatris Inc.
o Exhibit 153: Viatris Inc. - Overview
o Exhibit 154: Viatris Inc. - Business segments
o Exhibit 155: Viatris Inc. - Key offerings
o Exhibit 156: Viatris Inc. - Segment focus
• 13 Appendix
o 13.1 Scope of the report
o 13.2 Inclusions and exclusions checklist
o Exhibit 157: Inclusions checklist
o Exhibit 158: Exclusions checklist
o 13.3 Currency conversion rates for US$
o Exhibit 159: Currency conversion rates for US$
o 13.4 Research methodology
o Exhibit 160: Research methodology
o Exhibit 161: Validation techniques employed for market sizing
o Exhibit 162: Information sources
o 13.5 List of abbreviations
o Exhibit 163: List of abbreviations


Exhibits:
Exhibits1: Executive Summary - Chart on Market Overview
Exhibits2: Executive Summary - Data Table on Market Overview
Exhibits3: Executive Summary - Chart on Country Market Characteristics
Exhibits4: Executive Summary - Chart on Market by Geography
Exhibits5: Executive Summary - Chart on Market Segmentation by Drug Class
Exhibits6: Executive Summary - Chart on Market Segmentation by Route of Administration
Exhibits7: Executive Summary - Chart on Incremental Growth
Exhibits8: Executive Summary - Data Table on Incremental Growth
Exhibits9: Executive Summary - Chart on Vendor Market Positioning
Exhibits10: Parent market
Exhibits11: Market Characteristics
Exhibits12: Offerings of vendors included in the market definition
Exhibits13: Market segments
Exhibits14: Chart on Africa - Market size and forecast 2022-2027 ($ million)
Exhibits15: Data Table on Regional - Market size and forecast 2022-2027 ($ million)
Exhibits16: Chart on Africa: Year-over-year growth 2022-2027 (%)
Exhibits17: Data Table on Regional - Market size and forecast 2022-2027 ($ million)
Exhibits18: Historic Market Size - Data Table on HIV treatment drugs market in Africa 2017 - 2021 ($ million)
Exhibits19: Historic Market Size - Drug Class Segment 2017 - 2021 ($ million)
Exhibits20: Historic Market Size - Route Of Administration Segment 2017 - 2021 ($ million)
Exhibits21: Historic Market Size - Country Segment 2017 - 2021 ($ million)
Exhibits22: Five forces analysis - Comparison between 2022 and 2027
Exhibits23: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
Exhibits24: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
Exhibits25: Threat of new entrants - Impact of key factors in 2022 and 2027
Exhibits26: Threat of substitutes - Impact of key factors in 2022 and 2027
Exhibits27: Threat of rivalry - Impact of key factors in 2022 and 2027
Exhibits28: Chart on Market condition - Five forces 2022 and 2027
Exhibits29: Chart on Drug Class - Market share 2022-2027 (%)
Exhibits30: Data Table on Drug Class - Market share 2022-2027 (%)
Exhibits31: Chart on Comparison by Drug Class
Exhibits32: Data Table on Comparison by Drug Class
Exhibits33: Chart on Reverse transcriptase inhibitors - Market size and forecast 2022-2027 ($ million)
Exhibits34: Data Table on Reverse transcriptase inhibitors - Market size and forecast 2022-2027 ($ million)
Exhibits35: Chart on Reverse transcriptase inhibitors - Year-over-year growth 2022-2027 (%)
Exhibits36: Data Table on Reverse transcriptase inhibitors - Year-over-year growth 2022-2027 (%)
Exhibits37: Chart on Protease inhibitors - Market size and forecast 2022-2027 ($ million)
Exhibits38: Data Table on Protease inhibitors - Market size and forecast 2022-2027 ($ million)
Exhibits39: Chart on Protease inhibitors - Year-over-year growth 2022-2027 (%)
Exhibits40: Data Table on Protease inhibitors - Year-over-year growth 2022-2027 (%)
Exhibits41: Chart on Integrase inhibitors - Market size and forecast 2022-2027 ($ million)
Exhibits42: Data Table on Integrase inhibitors - Market size and forecast 2022-2027 ($ million)
Exhibits43: Chart on Integrase inhibitors - Year-over-year growth 2022-2027 (%)
Exhibits44: Data Table on Integrase inhibitors - Year-over-year growth 2022-2027 (%)
Exhibits45: Chart on Fusion inhibitors - Market size and forecast 2022-2027 ($ million)
Exhibits46: Data Table on Fusion inhibitors - Market size and forecast 2022-2027 ($ million)
Exhibits47: Chart on Fusion inhibitors - Year-over-year growth 2022-2027 (%)
Exhibits48: Data Table on Fusion inhibitors - Year-over-year growth 2022-2027 (%)
Exhibits49: Chart on Coreceptor antagonists - Market size and forecast 2022-2027 ($ million)
Exhibits50: Data Table on Coreceptor antagonists - Market size and forecast 2022-2027 ($ million)
Exhibits51: Chart on Coreceptor antagonists - Year-over-year growth 2022-2027 (%)
Exhibits52: Data Table on Coreceptor antagonists - Year-over-year growth 2022-2027 (%)
Exhibits53: Market opportunity by Drug Class ($ million)
Exhibits54: Chart on Route of Administration - Market share 2022-2027 (%)
Exhibits55: Data Table on Route of Administration - Market share 2022-2027 (%)
Exhibits56: Chart on Comparison by Route of Administration
Exhibits57: Data Table on Comparison by Route of Administration
Exhibits58: Chart on Oral drugs - Market size and forecast 2022-2027 ($ million)
Exhibits59: Data Table on Oral drugs - Market size and forecast 2022-2027 ($ million)
Exhibits60: Chart on Oral drugs - Year-over-year growth 2022-2027 (%)
Exhibits61: Data Table on Oral drugs - Year-over-year growth 2022-2027 (%)
Exhibits62: Chart on Injectable drugs - Market size and forecast 2022-2027 ($ million)
Exhibits63: Data Table on Injectable drugs - Market size and forecast 2022-2027 ($ million)
Exhibits64: Chart on Injectable drugs - Year-over-year growth 2022-2027 (%)
Exhibits65: Data Table on Injectable drugs - Year-over-year growth 2022-2027 (%)
Exhibits66: Market opportunity by Route of Administration ($ million)
Exhibits67: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits68: Chart on Market share by geography - 2022-2027 (%)
Exhibits69: Data Table on Market share by geography - 2022-2027 (%)
Exhibits70: Chart on Geographic comparison
Exhibits71: Data Table on Geographic comparison
Exhibits72: Chart on South Africa - Market size and forecast 2022-2027 ($ million)
Exhibits73: Data Table on South Africa - Market size and forecast 2022-2027 ($ million)
Exhibits74: Chart on South Africa - Year-over-year growth 2022-2027 (%)
Exhibits75: Data Table on South Africa - Year-over-year growth 2022-2027 (%)
Exhibits76: Chart on Nigeria - Market size and forecast 2022-2027 ($ million)
Exhibits77: Data Table on Nigeria - Market size and forecast 2022-2027 ($ million)
Exhibits78: Chart on Nigeria - Year-over-year growth 2022-2027 (%)
Exhibits79: Data Table on Nigeria - Year-over-year growth 2022-2027 (%)
Exhibits80: Chart on Kenya - Market size and forecast 2022-2027 ($ million)
Exhibits81: Data Table on Kenya - Market size and forecast 2022-2027 ($ million)
Exhibits82: Chart on Kenya - Year-over-year growth 2022-2027 (%)
Exhibits83: Data Table on Kenya - Year-over-year growth 2022-2027 (%)
Exhibits84: Chart on Uganda - Market size and forecast 2022-2027 ($ million)
Exhibits85: Data Table on Uganda - Market size and forecast 2022-2027 ($ million)
Exhibits86: Chart on Uganda - Year-over-year growth 2022-2027 (%)
Exhibits87: Data Table on Uganda - Year-over-year growth 2022-2027 (%)
Exhibits88: Chart on Rest of Africa - Market size and forecast 2022-2027 ($ million)
Exhibits89: Data Table on Rest of Africa - Market size and forecast 2022-2027 ($ million)
Exhibits90: Chart on Rest of Africa - Year-over-year growth 2022-2027 (%)
Exhibits91: Data Table on Rest of Africa - Year-over-year growth 2022-2027 (%)
Exhibits92: Market opportunity by geography ($ million)
Exhibits93: Impact of drivers and challenges in 2022 and 2027
Exhibits94: Overview on Criticality of inputs and Factors of differentiation
Exhibits95: Overview on factors of disruption
Exhibits96: Impact of key risks on business
Exhibits97: Vendors covered
Exhibits98: Matrix on vendor position and classification
Exhibits99: Abbott Laboratories - Overview
Exhibits100: Abbott Laboratories - Business segments
Exhibits101: Abbott Laboratories - Key news
Exhibits102: Abbott Laboratories - Key offerings
Exhibits103: Abbott Laboratories - Segment focus
Exhibits104: AbbVie Inc. - Overview
Exhibits105: AbbVie Inc. - Product / Service
Exhibits106: AbbVie Inc. - Key offerings
Exhibits107: Alpha Pharma - Overview
Exhibits108: Alpha Pharma - Product / Service
Exhibits109: Alpha Pharma - Key offerings
Exhibits110: Aspen Pharmacare Holdings Ltd. - Overview
Exhibits111: Aspen Pharmacare Holdings Ltd. - Business segments
Exhibits112: Aspen Pharmacare Holdings Ltd. - Key offerings
Exhibits113: Aspen Pharmacare Holdings Ltd. - Segment focus
Exhibits114: AstraZeneca Plc - Overview
Exhibits115: AstraZeneca Plc - Product / Service
Exhibits116: AstraZeneca Plc - Key news
Exhibits117: AstraZeneca Plc - Key offerings
Exhibits118: Aurobindo Pharma Ltd. - Overview
Exhibits119: Aurobindo Pharma Ltd. - Product / Service
Exhibits120: Aurobindo Pharma Ltd. - Key offerings
Exhibits121: Avacare Health - Overview
Exhibits122: Avacare Health - Product / Service
Exhibits123: Avacare Health - Key offerings
Exhibits124: Cipla Ltd. - Overview
Exhibits125: Cipla Ltd. - Business segments
Exhibits126: Cipla Ltd. - Key news
Exhibits127: Cipla Ltd. - Key offerings
Exhibits128: Cipla Ltd. - Segment focus
Exhibits129: F. Hoffmann La Roche Ltd. - Overview
Exhibits130: F. Hoffmann La Roche Ltd. - Business segments
Exhibits131: F. Hoffmann La Roche Ltd. - Key news
Exhibits132: F. Hoffmann La Roche Ltd. - Key offerings
Exhibits133: F. Hoffmann La Roche Ltd. - Segment focus
Exhibits134: Gilead Sciences Inc. - Overview
Exhibits135: Gilead Sciences Inc. - Product / Service
Exhibits136: Gilead Sciences Inc. - Key news
Exhibits137: Gilead Sciences Inc. - Key offerings
Exhibits138: GlaxoSmithKline Plc - Overview
Exhibits139: GlaxoSmithKline Plc - Business segments
Exhibits140: GlaxoSmithKline Plc - Key offerings
Exhibits141: GlaxoSmithKline Plc - Segment focus
Exhibits142: Merck and Co. Inc. - Overview
Exhibits143: Merck and Co. Inc. - Business segments
Exhibits144: Merck and Co. Inc. - Key news
Exhibits145: Merck and Co. Inc. - Key offerings
Exhibits146: Merck and Co. Inc. - Segment focus
Exhibits147: Sun Pharmaceutical Industries Ltd. - Overview
Exhibits148: Sun Pharmaceutical Industries Ltd. - Product / Service
Exhibits149: Sun Pharmaceutical Industries Ltd. - Key offerings
Exhibits150: Theratechnologies Inc. - Overview
Exhibits151: Theratechnologies Inc. - Product / Service
Exhibits152: Theratechnologies Inc. - Key offerings
Exhibits153: Viatris Inc. - Overview
Exhibits154: Viatris Inc. - Business segments
Exhibits155: Viatris Inc. - Key offerings
Exhibits156: Viatris Inc. - Segment focus
Exhibits157: Inclusions checklist
Exhibits158: Exclusions checklist
Exhibits159: Currency conversion rates for US$
Exhibits160: Research methodology
Exhibits161: Validation techniques employed for market sizing
Exhibits162: Information sources
Exhibits163: List of abbreviations